Nylen Kirk, Likhodii Sergei, Abdelmalik Peter A, Clarke Jasper, Burnham W McIntyre
University of Toronto Epilepsy Research Program, Department of Pharmacology, University of Toronto, Toronto, Ontario, Canada.
Epilepsia. 2005 Aug;46(8):1198-204. doi: 10.1111/j.1528-1167.2005.71204.x.
The pentylenetetrazol (PTZ) infusion test was used to compare seizure thresholds in adult and young rats fed either a 4:1 ketogenic diet (KD) or a 6.3:1 KD. We hypothesized that both KDs would significantly elevate seizure thresholds and that the 4:1 KD would serve as a better model of the KD used clinically.
Ninety adult rats and 75 young rats were placed on one of five experimental diets: (a) a 4:1 KD, (b) a control diet balanced to the 4:1 KD, (c) a 6.3:1 KD, (d) a standard control diet, or (e) an ad libitum standard control diet. All subjects were seizure tested by using the PTZ infusion test. Blood glucose and beta-hydroxybutyrate (beta-OHB) levels were measured.
Neither KD elevated absolute "latencies to seizure" in young or adult rats. Similarly, neither KD elevated "threshold doses" in adult rats. In young rats, the 6.3:1 KD, but not the 4:1 KD, significantly elevated threshold doses. The 6.3:1 KD group showed poorer weight gain than the 4:1 KD group when compared with respective controls. The most dramatic discrepancies were seen in young rats.
"Threshold doses" and "latency to seizure" data provided conflicting measures of seizure threshold. This was likely due to the inflation of threshold doses calculated by using the much smaller body weights found in the 6.3:1 KD group. Ultimately, the PTZ infusion test in rats may not be a good preparation to model the anticonvulsant effects of the KD seen clinically, especially when dietary treatments lead to significantly mismatched body weights between the groups.
采用戊四氮(PTZ)输注试验比较喂食4:1生酮饮食(KD)或6.3:1 KD的成年和幼年大鼠的癫痫发作阈值。我们假设两种KD都会显著提高癫痫发作阈值,并且4:1 KD将成为临床上使用的KD的更好模型。
将90只成年大鼠和75只幼年大鼠置于五种实验饮食之一:(a)4:1 KD,(b)与4:1 KD平衡的对照饮食,(c)6.3:1 KD,(d)标准对照饮食,或(e)随意进食的标准对照饮食。所有受试者均通过PTZ输注试验进行癫痫发作测试。测量血糖和β-羟基丁酸(β-OHB)水平。
两种KD均未提高幼年或成年大鼠的绝对“癫痫发作潜伏期”。同样,两种KD均未提高成年大鼠的“阈值剂量”。在幼年大鼠中,6.3:1 KD而非4:1 KD显著提高了阈值剂量。与各自的对照组相比,6.3:1 KD组的体重增加比4:1 KD组差。最显著的差异出现在幼年大鼠中。
“阈值剂量”和“癫痫发作潜伏期”数据提供了相互矛盾的癫痫发作阈值测量方法。这可能是由于使用6.3:1 KD组中发现的小得多的体重计算的阈值剂量虚高所致。最终,大鼠中的PTZ输注试验可能不是模拟临床上所见KD抗惊厥作用的良好准备,尤其是当饮食治疗导致组间体重显著不匹配时。